Kalypsys has unique capabilities that enable the dissection and epistasis analysis of cell signaling pathways and the intensive, data driven query of proven mechanisms of drug intervention. Our uHTS system, now in third generation design, is specifically designed to overcome the hurdles associated with cell based screening. It enables the mapping of signaling pathways or the assay of molecular target screens, including kinases, G-protein coupled receptors, nuclear receptors, either in biochemical format, within cell extracts, cell cultures or freshly isolated primary cells. The ability to query relevant, rather than engineered biology, offers insights and drug discovery opportunities that drive our pipeline and the portfolios of our Strategic Partners.
In discovery, we begin by applying our state-of-the-art automated technology platform to identify multiple lead series from our sizeable compound library and to perform in parallel a host of in vitro pharmacology, specificity, ADME and toxicology assays. We select only the best leads with superior drug-like profiles for medicinal chemistry and preclinical development. This approach allows us to build in quality and substantially reduce the time and cost to IND.